Share on StockTwits

Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki unloaded 3,600 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $77.80, for a total transaction of $280,080.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $81.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Pacira Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $75.40.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 0.05% on Thursday, hitting $74.75. 401,470 shares of the company’s stock traded hands. Pacira Pharmaceuticals has a 1-year low of $26.72 and a 1-year high of $83.41. The stock has a 50-day moving average of $70.73 and a 200-day moving average of $64.37. The company’s market cap is $2.665 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, May 1st. The company reported ($0.19) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. Pacira Pharmaceuticals’s revenue was up 216.4% compared to the same quarter last year. On average, analysts predict that Pacira Pharmaceuticals will post $-0.63 earnings per share for the current fiscal year.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.